4142:TPE
Adimmune Corp
NT$Â 16,80
arrow_upward
+0,60%(+0,100) 1D
13 nov, 13:30:11 GMT+8 · TWD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor 4142 genereren…
Openen
NT$Â 16,85
Hoog
NT$Â 17,15
Laag
NT$Â 16,75
Beursw.
7,22Â mld.
Gem. vol.
1,13Â mln.
Volume
724,64K
52 wk hoog
NT$Â 22,50
52 wk laag
NT$Â 15,65
WPA
NT$Â -0,34
Uitstaande aandelen
235,29Â mln.
Aantal medewerkers
564
Openen
NT$Â 16,85
Hoog
NT$Â 17,15
Laag
NT$Â 16,75
Beursw.
7,22Â mld.
Gem. vol.
1,13Â mln.
Volume
724,64K
52 wk hoog
NT$Â 22,50
52 wk laag
NT$Â 15,65
WPA
NT$Â -0,34
Uitstaande aandelen
235,29Â mln.
Aantal medewerkers
564
Nieuwsartikelen
Van webbronnen en nieuwspartners
TradingView
·
25 minuten geleden
SpaceX's S&P 500 bid gets new life as Elon Musk pitches Tesla merger
24/7 Wall St.
·
1 uur geleden
Union Pacific Beat the S&P 500 by 28.76 Points in the Past Year, and $1,000 From a Decade Ago Is Now Worth $3,693
Benzinga
·
29 minuten geleden
S&P 500 Rout Exposes Hidden Risk In 10% Buffered ETFs
Traders Union
·
3 uur geleden
Tom McClellan: NYSE Composite Index better comparison for A-D Line than S&P 500
Profiel
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Over Adimmune Corp